Subjects who participate in the study will self-administer the ultrasound device beginning at the onset of trapezius muscle pain, which is defined as a score of 3.0 or higher on a scale of 1-10. Subjects will be required to visit the clinical site at enrollment and weeks 2 and 4 for a total of 3 visits. Subjects will report their daily pain levels in a diary.